VANCOUVER, BC, Nov. 21,
2023 /PRNewswire/ - Numinus Wellness
Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX:
NUMIF), a mental health care company advancing innovative
treatments and safe, evidence-based psychedelic-assisted therapies,
will release its financial results for the quarter and year
ended August 31, 2023, after market close on Wednesday,
November 29, 2023.
Interested parties are invited to participate in the Company's
Q4 and year-end 2023 results conference call and webcast occurring
on the same day at 5:30 p.m. Eastern time / 2:30
p.m. Pacific time. During the call, Numinus executives will review
the Company's performance and recent initiatives.
A question-and-answer session will follow management's prepared
remarks. At this time, the operator will provide instructions for
qualified equity analysts to submit questions. Investors are
invited to submit questions by email to invest@numinus.com. A
selection of questions will be answered by management on the call,
and all emailed questions will be responded to by email.
To listen to the live webcast, please register at:
https://events.q4inc.com/attendee/375671679
The webcast will also be archived on the Events and
Presentations page of Numinus' Investor Relations website:
https://www.investors.numinus.com/events-and-presentations/
To participate in the live conference call, please use the
following dial-in information:
- 1 (888) 330-3632 (Toll-free North America)
- 1 (646) 960-0837 (International)
- Ask to participate in Numinus' Q4 2023 and Annual Results
Call
To avoid any delays in joining the call, please dial in at least
five minutes prior to the call start time. If prompted, please
provide conference passcode 3547386.
A replay of the conference call can also be accessed
after 8:30 p.m. Eastern time / 5:30 p.m. Pacific
time on November 29, 2023, at 1-800-770-2030 or
1-647-362-9199 (using passcode 3547386). The replay will be
available until December 13, 2023.
About Numinus
Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) helps people to
heal and be well through the development and delivery of innovative
mental health care and access to safe, evidence-based
psychedelic-assisted therapies. The Numinus model – including
psychedelic research and clinic care – is at the forefront of a
transformation aimed at healing rather than managing symptoms for
depression, anxiety, trauma, pain and substance use. At Numinus, we
are leading the integration of psychedelic-assisted therapies into
mainstream clinical practice and building the foundation for a
healthier society.
Learn more at www.numinus.com and follow us
on LinkedIn, Facebook, Twitter,
and Instagram.
View original
content:https://www.prnewswire.com/news-releases/numinus-to-host-q4-2023-and-annual-results-conference-call-on-november-29-2023-301994185.html
SOURCE Numinus Wellness Inc.